Literature DB >> 11274016

Determination of RhD zygosity: comparison of a double amplification refractory mutation system approach and a multiplex real-time quantitative PCR approach.

R W Chiu1, M F Murphy, C Fidler, B C Zee, J S Wainscoat, Y M Lo.   

Abstract

BACKGROUND: Rh isoimmunization and hemolytic disease of the newborn still occur despite the availability of Rh immunoglobulin. For the prenatal investigation of sensitized RhD-negative pregnant women, determination of the zygosity of the RhD-positive father has important implications. The currently available molecular methods for RhD zygosity assessment, in general, are technically demanding and labor-intensive. Therefore, at present, rhesus genotype assessment is most commonly inferred from results of serological tests. The recent elucidation of the genetic structure of the prevalent RHD deletion in Caucasians, as well as the development of real-time PCR, allowed us to explore two new approaches for the molecular determination of RhD zygosity.
METHODS: Two methods for RhD zygosity determination were developed. The first was based on the double Amplification Refractory Mutation System (double ARMS). The second was based on multiplex real-time quantitative PCR. For the double ARMS assay, allele-specific primers were designed to directly amplify the most prevalent RHD deletion found in RhD-negative individuals in the Caucasian population. The multiplex real-time quantitative PCR assay, on the other hand, involved coamplification and quantification of RHD-specific sequences in relation to a reference gene, albumin, in a single PCR reaction. A ratio, DeltaCt, based on the threshold cycle, was then determined and reflects the RHD gene dosage.
RESULTS: The allele-specific primers of the double ARMS assay reliably amplified the RHD-deleted allele and therefore accurately distinguished homozygous from heterozygous RhD-positive samples. The results were in complete concordance with serological testing. For the multiplex real-time quantitative PCR assay, the DeltaCt values clearly segregated into two distinct populations according to the RHD gene dosage, with mean values of 1.70 (SD, 0.17) and 2.62 (SD, 0.29) for the homozygous and heterozygous samples, respectively (P: <0.001, t-test). The results were in complete concordance with the results of serological testing as well as with the double ARMS assay.
CONCLUSION: Double ARMS and real-time quantitative PCR are alternative robust assays for the determination of RhD zygosity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11274016

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  29 in total

Review 1.  Molecular genetics and clinical applications for RH.

Authors:  Willy A Flegel
Journal:  Transfus Apher Sci       Date:  2011-01-28       Impact factor: 1.764

2.  RHD allelic identification among D-Brazilian blood donors as a routine test using pools of DNA.

Authors:  Mariza Mota; M Dezan; M C Valgueiro; A M Sakashita; J M Kutner; L Castilho
Journal:  J Clin Lab Anal       Date:  2012-02       Impact factor: 2.352

3.  Digital PCR for the molecular detection of fetal chromosomal aneuploidy.

Authors:  Y M Dennis Lo; Fiona M F Lun; K C Allen Chan; Nancy B Y Tsui; Ka C Chong; Tze K Lau; Tak Y Leung; Benny C Y Zee; Charles R Cantor; Rossa W K Chiu
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-30       Impact factor: 11.205

4.  Rapid detection and identification of mucormycetes in bronchoalveolar lavage samples from immunocompromised patients with pulmonary infiltrates by use of high-resolution melt analysis.

Authors:  Martina Lengerova; Zdenek Racil; Kristyna Hrncirova; Iva Kocmanova; Pavlina Volfova; Dita Ricna; Petr Bejdak; Mojmir Moulis; Zdenek Pavlovsky; Barbora Weinbergerova; Martina Toskova; Jiri Mayer
Journal:  J Clin Microbiol       Date:  2014-05-21       Impact factor: 5.948

5.  Rapid detection and identification of mucormycetes from culture and tissue samples by use of high-resolution melt analysis.

Authors:  Kristyna Hrncirova; Martina Lengerova; Iva Kocmanova; Zdenek Racil; Pavlina Volfova; Dita Palousova; Mojmir Moulis; Barbora Weinbergerova; Jana Winterova; Martina Toskova; Sarka Pospisilova; Jiri Mayer
Journal:  J Clin Microbiol       Date:  2010-06-30       Impact factor: 5.948

6.  RHCE*ceTI encodes partial c and partial e and is often in cis to RHD*DIVa.

Authors:  Connie M Westhoff; Sunitha Vege; Christine Halter Hipsky; Kim Hue-Roye; Tamara Copeland; Randall W Velliquette; Trina Horn; Christine Lomas-Francis; Marion E Reid
Journal:  Transfusion       Date:  2012-07-13       Impact factor: 3.157

7.  Variant RH alleles and Rh immunisation in patients with sickle cell disease.

Authors:  Emilia Sippert; Claudia R Fujita; Debora Machado; Glaucia Guelsin; Ane C Gaspardi; Jordão Pellegrino; Simone Gilli; Sara S T O Saad; Lilian Castilho
Journal:  Blood Transfus       Date:  2014-06-19       Impact factor: 3.443

8.  A novel RHCE*ce 48C, 733G allele with Nucleotide 941C in Exon 7 encodes an altered red blood cell e antigen.

Authors:  Kim Hue-Roye; Christine Halter Hipsky; Randall W Velliquette; Akiko Fuchisawa; Christine Lomas-Francis; Carolyn Hoppe; Marion E Reid
Journal:  Transfusion       Date:  2011-01       Impact factor: 3.157

9.  The JAL antigen (RH48) is the result of a change in RHCE that encodes Arg114Trp.

Authors:  Connie M Westhoff; Sunitha Vege; Dwane Wylie; Pam Nickle; Christine Lomas-Francis; Kim Hue-Roye; Marion E Reid
Journal:  Transfusion       Date:  2008-12-23       Impact factor: 3.157

10.  DIIIa and DIII Type 5 are encoded by the same allele and are associated with altered RHCE*ce alleles: clinical implications.

Authors:  Connie M Westhoff; Sunitha Vege; Christine Halter-Hipsky; Trina Whorley; Kim Hue-Roye; Christine Lomas-Francis; Marion E Reid
Journal:  Transfusion       Date:  2010-01-15       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.